MRI assessment of blood-brain barrier function in CADASIL patients
MRI Study of Blood-brain Barrier Function in CADASIL
This study is testing a new MRI method to see if the blood-brain barrier works differently in people with CADASIL compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05902039 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes a novel MRI technique called diffusion prepared pseudo-continuous ASL (DP-pCASL) to evaluate the function of the blood-brain barrier (BBB) in patients diagnosed with CADASIL, a hereditary cerebral small vessel disease. The researchers aim to determine if the water exchange rate across the BBB is altered in these patients and to explore the relationship between this rate and various MRI and clinical features. By comparing the BBB function in CADASIL patients to healthy controls, the study seeks to clarify the controversial findings regarding BBB abnormalities in this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 20-70 with a confirmed diagnosis of CADASIL.
Not a fit: Patients with other significant cerebrovascular diseases or those who do not have a confirmed diagnosis of CADASIL may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of BBB dysfunction in CADASIL, potentially leading to improved diagnostic and therapeutic strategies for patients.
How similar studies have performed: While there have been studies investigating BBB function in other contexts, this approach using DP-pCASL in CADASIL is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with CADASIL confirmed by gene or/and skin biopsy. 2. The age range is 20-70 years old. 3. There is no contraindication to MRI examination, and the informed consent is signed. Exclusion Criteria: 1. Combined with definite cerebrovascular disease, or combined with brain tumor, brain trauma and other causes of brain diseases. 2. CADASIL is not confirmed. 3. There are contraindications to examination or refusal to sign the informed consent.
Where this trial is running
Beijing
- Peking University First Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Chen Ling, PhD
- Email: lnyy.chen@foxmail.com
- Phone: +86 18101358135
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.